Introduction {#Sec1}
============

Glucokinase (*GCK*) plays a crucial role in regulation and integration of glucose metabolism in beta cells and hepatocytes. Enzymatic activity of *GCK* is directly associated with insulin secretion which results in glucokinase acting as the main glucosensor for the beta cells \[[@CR1]--[@CR3]\].

Heterozygous *GCK* mutations result in diabetes following a dominant mode of inheritance (GCK-MODY) which in some cases may be misdiagnosed as idiopathic type 1 diabetes \[[@CR4]\]. The clinical picture usually encompasses moderately elevated fasting hyperglycemia with mildly increased glycated hemoglobin levels. Ketoacidosis in patients with GCK-MODY is rarely observed, as are chronic complications of diabetes \[[@CR5], [@CR6]\].

Clinical presentation of diabetes among patients with biallelic (homozygous or compound heterozygous) mutations of the *GCK* gene is dramatically different, e.g., diabetes that develop during the initial days of life is difficult to control and generally unresponsive to treatment other than with insulin. Such a defect is detected in 5--10% of patients with persistent neonatal diabetes (PND) \[[@CR7], [@CR8]\]. Symptoms of PND with biallelic *GCK* mutations manifest during the initial days of life, with pronounced hyperglycemia, ketoacidosis, and severe clinical condition \[[@CR9], [@CR10]\]. Insulin-based treatment is ubiquitous, but achievement of optimal metabolic control may be difficult possibly due to the mixed pancreato-hepatic origin of the disorder. This report presents a large GCK-MODY family with broad spectrum of clinical diabetic phenotype among affected family members.

Materials and methods {#Sec2}
=====================

The study was conducted in accordance with the Declaration of Helsinki as revised in 2000 and accepted by the Institutional Bioethics Committee. Participants expressed their informed consent for participation in the study.

The authors sought to evaluate the clinical and genetic characteristics of a large family with GCK-MODY with one individual manifesting severe symptoms of diabetes during the neonatal period. For further evaluation, the patient, her sister, and two additional family members with diabetes were subjected to continuous glucose monitoring (CGM) examination, by means of Medtronic Diabetes CGMS (Medtronic, Northridge, CA, USA). Registered data from the CGMS Digital Recorder and the blood glucose meter were downloaded and analyzed with the appropriate dedicated software.

Genetic analysis {#Sec3}
----------------

DNA was extracted from peripheral blood cells drawn into EDTA-coated vials. Isolation was performed according to the manufacturer's protocol using QiaAmp DNA mini kits from Qiagen (Qiagen, Hilden, Germany). PCR amplification and DNA purification were carried out using standard methods \[[@CR11], [@CR12]\]. DNA sequencing was performed using BigDye Seq kit v3.1 (Applied Biosystems, Foster City, CA, USA) and pairs of specific oligonucleotide primers spanning the coding and promoter sequence of the *GCK* gene. Identification of mutations was performed by direct sequencing using the ABI 3130 genetic analyzer and DNA Sequencing Analysis Software (Applied Biosystems, Foster City, CA, USA). For the comparative analysis of evaluated sequences, human genome reference using Sequencher software v4.1.4 (GeneCodes, Ann Arbor, MI, USA) was used. DNA was also subjected to multiplex ligation-dependent probe amplification (MLPA) testing according to the manufacturer's protocol using a commercially available set MODY-P241 (MRC-Holland, Netherlands) to search for deletions in known monogenic diabetes genes including *GCK*. The same approach was implemented for mutation detection in coding and promoter regions (approximately 1,000 bp upstream from the first exon) of *HNF1A*, *HNF4A*, *PDX1*, *HNF1B, NEUROD1, KCNJ11, ABCC8,* and *INS* gene in the patient with onset of diabetes during the neonatal period. All genetic analysis was performed in the Immunopathology and Genetics Laboratory at the Department of Pediatrics, Oncology, Hematology, and Diabetology in Lodz, which is reference ISO9001 certified laboratory with European Molecular Genetics Quality Network (EMQN) collaboration.

Statistical analysis {#Sec4}
--------------------

Continuous variables were presented as medians and 25--75% or as means with standard deviation depending on distribution. Normalization was performed against region-specific means and standard deviation with values presented as standard deviation scores (SDS). Comparisons of continuous variables between two groups were made using the Mann--Whitney's *U* test. Statistical significance was declared when a *P* value 0.05 was observed. Statistica 8.0 (Statsoft, Tulsa, OK, USA) statistical software was used to perform these analyses.

Subjects studied {#Sec5}
----------------

Based on the above criteria, the authors found one child positive for a heterozygous *GCK* mutation who was diagnosed with PND (denoted as No5109 in the Nationwide Registry of Monogenic Diabetes). The patient, a female infant, presented with severe hyperglycemia (765 mg/dl), dehydration, glucosuria, and ketoacidosis (pH 7.09, BE 14 mM) on the day after her birth. The child was delivered by natural means from a second, uneventful pregnancy during the 36th week of gestation. Her birth weight equaled 1,760 g (\<2 SDS), body length---46.3 cm (SDS −1.73), head circumference---30 cm (SDS −2.23), thorax circumference---26 cm (SDS −3.17), Apgar score equaled 7 on the first and 9 on the third minute of life.

For the first 72-h after diagnosis, she was treated with intravenous insulin (dose range: 0.1--0.3 units/kg/h) due to persistent hyperglycemia (mean value from that period equaled 340 mg/dl). On the 4th day of life, the girl was transferred from the Neonatal Care Unit to the Diabetes Unit. Subsequently, she was given insulin in multiple daily injections (mean daily dose equaled 0.9 U/kg). In the 7th week of life, continuous subcutaneous insulin infusion (CSII) therapy using a personal insulin pump was started. The insulin dose was reduced to 0.4 units/kg per day, and the blood glucose levels gradually normalized.

Follow-up visits after three and 6 months of treatment showed that fasting and glucagon stimulated C-peptide level was \<0.5 ng/ml and HbA1c levels 6.5% (47.5 mmol/mol) and 8.3% (67.2 mmol/mol), respectively. No islet cell, anti-GAD65, anti-insulinoma-associated antigen-2, and anti-insulin autoantibodies were detected. At the age of 6 months, the girl weighted 6,400 g (SDS −1.37) and achieved all the psychomotor milestones adequate for that age.

Currently, at the age of 3 years, the child remains treated with CSII. Her daily insulin dose ranges between 0.6 and 0.8 units/kg per day, but metabolic control of diabetes is still not satisfactory (median HbA1c level equaled 8.1% (65.0 mmol/mol)), whereas psychomotor development was adequate for her age.

DNA sequencing revealed that the proband had heterozygous missense mutation C.667G \> A in the *GCK* gene, which resulted in the amino acid substitution of glycine to serine at the 223rd position (p.Gly223Ser) (Fig. [1](#Fig1){ref-type="fig"}). Severe diabetes presentation, which is unusual among the carriers of heterozygous *GCK* mutation, suggested a possible biallelic genetic background (compound heterozygous or homozygous). Since only one heterozygous mutation in *GCK* locus was found, the authors decided to perform genetic screening for mutation in other known monogenic diabetes genes using both DNA sequencing (for point mutation detection) and MLPA techniques (for deletions/amplifications). These analyses did not reveal any other potentially causative lesions except the original one---the p.Gly223Ser in *GCK*.Fig. 1**a** DNA sequencing results confirming the p.Gly223Ser mutation in a healthy family member (*top* chromatogram) and patient No5109 (*bottom* chromatogram); **b** full pedigree of the presented GCK-MODY family. Patient No5109---marked with an *arrow*---was diagnosed with neonatal diabetes. All patients marked as affected had diabetes or impaired fasting glucose and were heterozygous with the same p.Gly223Ser mutation located in the exon 6 of the *GCK*. *N* wild type, *M* p.Gly223Ser mutation

Mother of the presented patient (aged 21) was diagnosed with gestational diabetes mellitus that persisted after delivery. At the moment of evaluation, the state of her diabetes remained well controlled (HbA1c 5.8% (39.9 mmol/mol)) and she was able to maintain near-normoglycemic levels using diet only. Her fasting C-peptide level was well within the normal range (1.42 pmol/ml) and suggested retained beta cell function. Her siblings: one sister and one brother have been diagnosed initially with type 1 diabetes mellitus, which upon later verification turned out to be GCK-MODY. In depth evaluation of the presented family revealed that eleven out of 27 available family members had diabetes or impaired glucose tolerance (IGT). This observation gave strong evidence toward a dominant mode of inheritance. Complete pedigree analysis of the described family and DNA sequencing results are depicted on Fig. [1](#Fig1){ref-type="fig"} (a--b). Analysis of *GCK* gene showed that all subjects with diabetes (*n* = 9) or IGT (*n* = 2) were heterozygous carriers of the p.Gly223Ser substitution, and this mutation was absent in healthy family members. Interestingly, all affected family members but patient No5109, had mild clinical presentation of the disease, retained C-peptide levels, and in all cases but one did not require insulin treatment (Table [1](#Tab1){ref-type="table"}). The CGM examination performed in patient No5109 showed 24-h glucose variability that was markedly different from typical GCK-MODY and similar to that observed among patients with type 1 diabetes (Fig. [2](#Fig2){ref-type="fig"} a--c).Table 1Clinical characteristics of the presented familyCharacteristicPatient No5109Other family members with diabetes or IGTHealthy family members*Pn*11115--% maleFemale64%40%--Ketoacidosis at diagnosispH 7.09\
BE 14 mMNoneNA--Age at diagnosis (years)2nd day after birth17.5 (9.2--20.7)NA--Fasting glucose at diagnosis (mg/dl)765126 (115--132)90 (79--102)\<10^−5^HbA1c at diagnosis (%) (mmol/mol)8.6\
70.56.2 (5.5--6.9)\
44.3 (36.6--51.9)NA--TreatmentInsulinInsulin-1\
Oral agents-5\
Diet-5NA--Median HbAc (%)8.1 (7.2--8.4)\
65 (55.2--68.3)6.1 (5.5--6.4)\
43.2 (36.6--46.5)5.4 (5.1--5.6)\
35.5 (32.2--37.7)0.002Fasting C-peptide (pmol/ml)\<0.51.17 (0.7--1.5)1.01 (0.5--1.4)0.53*P* values are given for comparisons between the healthy family members and the p.Gly223Ser mutation carriers. Data are presented as medians with interquartile ranges unless noted otherwise*NA* not applicable, *IGT* impaired glucose toleranceFig. 2Continuous glucose monitoring results of patient No5109 with a phenotype of neonatal diabetes and heterozygous p.Gly223Ser mutation in glucokinase (**a**), her sister with mild phenotype and the same heterozygous p.Gly223Ser mutation (**b**) and a 3-year-old patient with type 1 diabetes mellitus (**c**)

Discussion {#Sec6}
==========

The majority of patients with heterozygous mutations of the glucokinase gene (GCK-MODY) may be diagnosed on clinical features. Symptoms of this form of diabetes are usually: fasting hyperglycemia \>100 mg/dl, HbA1c levels elevated above normal limit but rarely exceeding 7.5% (58.5 mmol/mol), and small incremental rise of glycemia in oral glucose tolerance test \[[@CR13]\]. The diagnosis is most often stated during the initial two decades of life \[[@CR14]\]. The p.Gly223Ser mutation known to cause GCK-MODY in the proband's family segregated with disease status in all individuals of the family, and thus a diagnosis of GCK-MODY was confirmed in 12 out of 27 individuals. The p.Gly223Ser mutation is a known defect of *GCK* leading to the development of typical MODY diabetes, which affects glucokinase activity in functional studies \[[@CR15]--[@CR17]\].

The observed low fasting C-peptide level---a trait generally attributed to homozygous *GCK* mutations \[[@CR9], [@CR10]\]---was the main feature confirming severe beta cell insufficiency in the presented individual. In her family, however, the level of C-peptide did not differ significantly upon the dependency of mutation carriage. This observation suggested the potential for an additional de novo mutation or a strong modulating effect of other genetic factors being active in the proband with neonatal diabetes.

GCK-MODY may be diagnosed in the neonatal period, but the clinical phenotype is most often mild with fasting plasma glucose within 6.0--7.6 mmol/l range \[[@CR18], [@CR19]\]. Thus, the authors were surprised to observe neonatal diabetes with such acute onset as mentioned earlier. Reports showed signs of ketoacidosis and significant hyperglycemia at onset to be extremely rare. Identification of a heterozygous mutation in *GCK* during the neonatal period is still a rare occurrence and, as was the case in the presented individual, may be a direct consequence of known GCK-MODY familial background, which guides the physician to proper diagnosis and rapid deployment of genetic diagnostics methods. A similar phenotype occurring in a non-familial setting would most likely result primarily in sequencing of *KCNJ11, ABCC8,* and *INS* genes as the most common causes of non-consanguineous cases of neonatal diabetes \[[@CR20]\]. The relatively severe clinical course of diabetes with ketoacidosis and low birth weight suggested that the disease might have been actually caused by an additional de novo mutation in one of those genes exacerbating the effect of *GCK* mutations.

Coexistence of mutations in two separate genes causative of monogenic diabetes has been reported in several reports and different combinations. Cervin et al. \[[@CR21]\] described the coexistence of *HNF1A* mutation with mitochondrial diabetes. Coexistence of *KCNJ11* with *GCK* mutations has been described among Italian patients with monogenic diabetes \[[@CR22]\]. Combinations of HNF1A and HNF4A mutations were also reported in patients with monogenic diabetes \[[@CR23], [@CR24]\]. A report by Odem et al. \[[@CR25]\] suggested that coexistence of benign mutations in *GCK* and *PDX1* could potentially lead to diabetes due to the joint effect of both defects, although this conclusion was not supported by any functional studies. Attempts to detect coexisting mutations in other MODY genes were therefore made, but no mutations were found in any of known MODY or PND genes. Similarly, no clinical features suggesting the presence of defects in genes associated with syndromic diabetes were found. Nevertheless, the possibility that patient No5109 had a de novo mutation in a yet undiscovered gene resulting in monogenic diabetes in addition to the p.Gly223Ser mutation of *GCK* remains the most likely explanation of the described phenotype discrepancy. This will necessitate reevaluation as new genes responsible for this disease are discovered and defined similarly to other patients with PND of unknown etiology.

The matter of increased "diabetes awareness" of the mother could contribute toward earlier diagnosis of diabetes in her second child if hyperglycemia was the only symptom at presentation, but cannot possibly explain the acute onset of symptoms. Finally, a plausible explanation for the observed phenotype is a modulating effect of common polymorphisms increasing the risk for developing diabetes. Potential candidates could include polymorphisms or mutations in genes participating in determining insulin secretion, insulin resistance, or beta cell apoptosis \[[@CR26]--[@CR30]\]. However, as the question which loci would be the most likely to exert such effect is unresolved, this hypothesis is purely speculative.

In conclusion, a heterozygous *GCK* mutation is a factor leading to monogenic diabetes with very discrepant phenotypes of the disease. Even within a single family the clinical presentation may range from severe diabetes manifesting in infancy to mild hyperglycemia detected accidentally during later stages of life. The possibility of additional, unknown genetic defects also seems to be the most likely explanation for the above-stated unusual presentation of GCK-MODY.
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